Following expanded FDA approval for pediatric patients, the over-the-counter Stelo continuous glucose monitor is adding AI ...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...
FDA clears Dexcom Stelo as the first OTC CGM for children, raising new questions around app access, caregiver oversight, ...
Over-the-counter continuous glucose monitors have gained popularity over recent years. These devices are designed to help ...
President and CEO Jake Leach said, “Glucose matters for everyone.” The company plans to broaden access to glucose biosensing ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...
DexCom DXCM recently announced that it will begin rolling out its fully reimagined Stelo app experience in the United States ...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom ...
Add Yahoo as a preferred source to see more of our stories on Google. Four years ago, my life changed after a heart attack at the age of 33. While a quick coronary angioplasty meant my heart was ...
Dexcom on Tuesday announced that its new over-the-counter continuous glucose monitor called Stelo has been cleared for use by the FDA. The new CGM is designed for patients with Type 2 diabetes who do ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results